Can we prevent parkinson's disease? - PubMed (original) (raw)

Review

. 2009 Jan 1;14(5):1642-60.

doi: 10.2741/3331.

Affiliations

• PMID: 19273153
• DOI: 10.2741/3331

Free article

Review

Can we prevent parkinson's disease?

Christine R Swanson et al. Front Biosci (Landmark Ed). 2009.

Free article

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects 1 million people in the United States. Although the cause of PD remains unknown, a number of factors that increase the risk of developing this disease have been identified. Other factors that may prevent or slow down PD development and progression have also been found. In this review, we describe current basic, clinical and epidemiological findings on risk and neuroprotective factors and discuss how they can affect PD.

PubMed Disclaimer

Similar articles

• Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?
  Belvisi D, Pellicciari R, Fabbrini G, Tinazzi M, Berardelli A, Defazio G. Belvisi D, et al. Neurobiol Dis. 2020 Feb;134:104671. doi: 10.1016/j.nbd.2019.104671. Epub 2019 Nov 6. Neurobiol Dis. 2020. PMID: 31706021 Review.
• Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.
  Ross GW, Petrovitch H. Ross GW, et al. Drugs Aging. 2001;18(11):797-806. doi: 10.2165/00002512-200118110-00001. Drugs Aging. 2001. PMID: 11772120 Review.
• Oxidative stress and Parkinson's disease: New hopes in treatment with herbal antioxidants.
  Sarrafchi A, Bahmani M, Shirzad H, Rafieian-Kopaei M. Sarrafchi A, et al. Curr Pharm Des. 2016;22(2):238-46. doi: 10.2174/1381612822666151112151653. Curr Pharm Des. 2016. PMID: 26561062 Review.
• Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
  Carroll CB, Webb D, Stevens KN, Vickery J, Eyre V, Ball S, Wyse R, Webber M, Foggo A, Zajicek J, Whone A, Creanor S. Carroll CB, et al. BMJ Open. 2019 Oct 7;9(10):e029740. doi: 10.1136/bmjopen-2019-029740. BMJ Open. 2019. PMID: 31594876 Free PMC article.
• Neuroprotection in Parkinson's disease.
  Schapira AH. Schapira AH. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S41-3. doi: 10.1016/S1353-8020(09)70834-X. Parkinsonism Relat Disord. 2009. PMID: 20123556 Review.

Cited by

• Cell-based therapies for Parkinson's disease: past, present, and future.
  Fitzpatrick KM, Raschke J, Emborg ME. Fitzpatrick KM, et al. Antioxid Redox Signal. 2009 Sep;11(9):2189-208. doi: 10.1089/ars.2009.2654. Antioxid Redox Signal. 2009. PMID: 19485712 Free PMC article. Review.
• Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.
  Emborg ME, Moirano J, Raschke J, Bondarenko V, Zufferey R, Peng S, Ebert AD, Joers V, Roitberg B, Holden JE, Koprich J, Lipton J, Kordower JH, Aebischer P. Emborg ME, et al. Neurobiol Dis. 2009 Nov;36(2):303-11. doi: 10.1016/j.nbd.2009.07.022. Epub 2009 Aug 4. Neurobiol Dis. 2009. PMID: 19660547 Free PMC article.
• The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.
  Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME. Swanson CR, et al. J Neuroinflammation. 2011 Aug 5;8:91. doi: 10.1186/1742-2094-8-91. J Neuroinflammation. 2011. PMID: 21819568 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • IMR Press

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information